Fact CheckerSign in

NCT05440838Recruiting

Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.

Source: ClinicalTrials.gov · Last updated 6 Mar 2026

Brief summary (registry, in English)

First-line treatment for patients with polycythemia vera, essential thrombocythemia, and pre-myelofibrosis is based on hydroxyurea or pegylated interferon. The objective of treatment is to prevent thrombotic complications and leukemic transformation. Despite overall good response rates, some patients do not respond to treatment and others lose their response over time. Both situations are associated with worse survival and there are to date no clear predictive factors for response although the existence of additional mutations seems unfavorable. In this exploratory study, we hypothesize that biological factors at diagnosis are associated with hematological response at 12 months. We will more specifically study the association between mutational profile, assessed by next-generation sequencing, and cytokine profile with hematological response. This study will help in identifying patients who will not respond to hydroxyurea or pegylated interferon and give the opportunity to try other treatments upfront, in the perspective of precision medicine. On the basic science side, this study will help in understanding the molecular and immunological factors involved in resistance to treatment.

Status (registry)
Recruiting
Study type
Observational
Enrollment
120 (estimated)
First submitted
10 Jun 2022
Start date
17 May 2023
Primary completion date
17 Feb 2027
Lead sponsor
University Hospital, Angers
NCT number
NCT05440838

What you commit to

  • Study type: Observational
  • Planned participants: 120
  • From 17 May 2023 to the primary completion date, 17 Feb 2027
  • 6 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous treatment.

Other illness

  • Other on-going malignancy, including overt myelofibrosis.

Other

  • Other treatment such as phlebotomy solely, ruxolitinib, anagrelide, or pipobroman.

Who the study is looking for

  • Adults with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis.
  • Indication for first-line treatment with hydroxyurea or pegylated interferon.
  • Consent to participate.
  • Affiliated to social security.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (6)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
CHU Angers
Coordinator of this site? Confirm its status
AngersFranceRecruiting
Chu Brest
Coordinator of this site? Confirm its status
BrestFranceRecruiting
CHU Nantes
Coordinator of this site? Confirm its status
NantesFranceRecruiting
CHU Poitiers
Coordinator of this site? Confirm its status
PoitiersFranceRecruiting
CHU Rennes
Coordinator of this site? Confirm its status
RennesFranceRecruiting
CHU Tours
Coordinator of this site? Confirm its status
ToursFranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.